Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work

J&J Veteran To Continue Rebuilding In 2023

Executive Summary

After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.

You may also be interested in...



Galapagos Loses Potential Ticket To America As Crohns Trial Flops

The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.

Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T

The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.

Toledo Data Fail To Give Galapagos A Lift

Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel